Canine Leishmaniasis Treatment Guidelines for Dogs

Treatment for canine leishmaniasis usually involves a combination of medication and supportive care. The goal of treatment is to reduce the severity of symptoms and manage the disease.

The most common medication used to treat canine leishmaniasis is miltefosine, an oral medication that has been shown to be effective in reducing parasite loads.

Treatment typically lasts for 30 days, but may be extended if the dog's condition does not improve.

A different take: Canine Leishmaniasis

Leishmaniasis in dogs is diagnosed based on a dog's medical and travel history, especially if they've traveled to an area with endemic leishmaniasis.

Clinical signs are also taken into account. General blood tests may reflect changes if specific organs are affected.

A blood test is usually performed, along with a urine test and tissue biopsies. Occasionally, the organism can be found on aspirates of lymph nodes or smears made from skin lesions.

Expand your knowledge: Canine Distemper Test

The immune response plays a key role in the progression of Leishmania spp infection. This is a crucial aspect of understanding how the disease progresses.

The immune response is like a delicate balance, and when it's disrupted, it can lead to the progression of Leishmania spp infection.

Here's a brief overview of the key factors involved in the immune response:

Leishmaniasis diagnosis is a multi-step process that involves a dog's medical and travel history, especially if they've traveled to an area with endemic leishmaniasis.

Clinical signs are also taken into account, which can include various symptoms.

Blood tests are usually performed, as well as urine tests, to help diagnose leishmaniasis.

Tissue biopsies may also be necessary to confirm the diagnosis.

A PCR blood test can be sent to a laboratory for further analysis, which has the best chance of detecting leishmaniasis.

However, this test is not 100% definitive, so other tests may still be needed.

Antibodies may be seen in the blood, depending on how long the dog has been infected.

General blood tests may reflect changes if specific organs are affected, providing more information for the diagnosis.

Explore further: Canine Brucellosis Test

Leishmaniasis can cause a range of clinical signs in dogs and cats, depending on the form of the disease.

The visceral form of the disease, which affects about 90% of dogs, includes symptoms such as fever, anorexia, and weakness.

Additional reading: What Is Canine Lupus

Dogs with visceral leishmaniasis may also experience severe weight loss, diarrhea, vomiting, increased drinking and urination, and bleeding from the nose.

In addition, about one-third of dogs will develop swollen lymph nodes and an enlarged spleen, which can progress to kidney failure.

The cutaneous form of the disease, which is more common in cats, includes symptoms such as thickening and hardening of the tissues on the muzzle and footpads.

Many dogs will lose the pigment or dark coloring of these tissues as the disease progresses, and nodules or hard lumps may form in the skin.

The coat often appears dull and brittle with areas of hair loss, and the nails may grow long and curve abnormally.

Virtually all dogs that acquire leishmaniasis will develop the visceral form of the disease, and 90% of those dogs will also have cutaneous involvement.

Additional reading: Dog Vision Loss

Most cases of leishmaniasis are outpatient, but renal disease requires hospitalization and fluid therapy for supportive care.

The treatment of leishmaniasis involves a combination of medications, including leishmanicidal agents and immunostimulants.

In the United States, there are no FDA-approved drugs for the treatment of leishmaniasis in non-human species, making sourcing medications challenging.

The most effective treatment regimens include a combination of subcutaneous meglumine antimoniate or oral miltefosine with allopurinol to reduce the parasite load.

Allopurinol is widely available in the United States and can be used off-label to treat canine leishmaniasis.

Medical therapy for canine leishmaniasis does not cure the disease but can result in improved clinical signs, normalization of blood work, and decreased parasite burden.

The treatment of canine leishmaniasis requires lifetime monitoring of antibody-positive dogs, including regular examinations, laboratory screening, and quantitative titer testing.

Repeat serologic testing with a quantitative assay is recommended 6 months after starting therapy and then every 6 to 12 months.

Leishmania-positive dogs should be sterilized and not used as blood donors.

Here are some key treatment options for canine leishmaniasis:

Most cases of canine leishmaniasis are treated on an outpatient basis, but some cases may require hospitalization and fluid therapy for supportive care.

The goal of treatment is to resolve the clinical signs of leishmaniasis, and there are many treatments available that are often used in combination.

A combination of antimonials, such as meglumine antimoniate, or miltefosine with allopurinol is the therapy of choice for treating canine leishmaniasis.

In some cases, domperidone has demonstrated efficacy in disease control, especially in mild cases or seropositive dogs without signs.

Proteinuria, if present, can be treated with ACE inhibitors, such as benazepril.

Ocular lesions, such as keratoconjunctivitis and uveitis, require specific treatment.

Immunomodulating/potentiating drugs can be administered at 0.5 mg/kg once a day for 1 month.

Sodium stibogluconate has been used to treat leishmaniasis, but it is difficult to obtain.

Alternative treatments include meglumine antimonite, allopurinol with or without domperidone, and marbofloxacin.

Supportive treatments include intravenous fluids, special therapeutic diets, and antibiotics if the skin lesions are infected.

Solitary skin lesions can be removed surgically.

Unfortunately, there is no cure for canine leishmaniasis, and dogs may relapse.

In the United States, there are no FDA-approved drugs for the treatment of leishmaniasis in non-human species, making sourcing medications challenging.

Allopurinol is widely available in the United States and can be used off-label to treat canine leishmaniasis.

Dogs receiving allopurinol should be transitioned to low-purine dog food to minimize the risk of xanthine urolithiasis.

Medical therapy can result in improved clinical signs, normalization of blood work, and decreased parasite burden.

However, no therapy has been shown to completely eradicate the Leishmania parasite, and dogs remain lifetime reservoirs of infection.

To prevent Leishmania transmission, it is recommended to use repellent insecticides, such as synthetic pyrethroids, and to sterilize Leishmania-positive dogs.

Here are some common treatments for canine leishmaniasis:

Note: Treatment options may vary by geographic area, strain of infection, and exhibited symptoms, so it's best to coordinate with veterinary research hospitals for the most effective treatment plan.

Regular monitoring is crucial to ensure the effectiveness of treatment and catch any potential relapse. Patients should be evaluated after 1, 3, and 6 months of treatment and then once every 6 months for life.

Real-time PCR testing can help identify relapse by detecting a high parasitic load in the sample. This allows for prompt action to be taken to prevent the disease from spreading.

Topical insecticides have shown great promise in preventing canine leishmaniasis. A deltamethrin-impregnated collar, for example, can provide >90% protection when used once every 5 months, while topical permethrins can offer similar protection when used once every 3 weeks.

Here's a quick rundown of the evaluation schedule:

These regular check-ups should include a thorough examination, CBC, serum biochemistry profile, urinalysis, and serology (once every 6 months).

Prevention is key to reducing the risk of disease. Topical insecticides, such as deltamethrin-impregnated collars, can provide over 90% protection against disease when used every 5 months.

Using topical permethrins every 3 weeks can also be an effective preventive measure. Regular use of these insecticides can lower disease prevalence when used extensively.

Two protein vaccines are available, one in Europe and one in Brazil, both of which use a saponin as a coadjuvant. These vaccines offer an alternative to insecticides for preventing disease.

Recent data suggest that domperidone, when used regularly, may also have preventive properties. However, more research is needed to confirm this, particularly through large controlled studies.

Patient Monitoring is crucial in the treatment and management of leishmaniasis.

Patients should be evaluated after 1, 3, and 6 months of treatment and then once every 6 months for life. This regular evaluation helps monitor the effectiveness of the treatment and catch any potential relapses early.

A thorough examination, CBC, serum biochemistry profile, urinalysis, and serology (once every 6 months) should be included in the evaluation process. These tests provide valuable information about the patient's overall health and the presence of any potential complications.

Real-time PCR testing can help identify relapse by detecting a high parasitic load in the sample. This testing can be particularly useful in detecting relapses early, allowing for prompt treatment and minimizing the risk of complications.

Here's a summary of the recommended evaluation schedule:

By following this evaluation schedule and including the recommended tests, you can effectively monitor the patient's progress and catch any potential relapses early.